Stockscreener 앱 받기
28.68
2.87%
0.80
전일 마감가:
$27.88
열려 있는:
$27.76
하루 거래량:
134.77K
Relative Volume:
0.81
시가총액:
$1.88B
수익:
-
순이익/손실:
$-198.12M
주가수익비율:
-8.5127
EPS:
-3.3691
순현금흐름:
$-159.74M
1주 성능:
+3.02%
1개월 성능:
+12.82%
6개월 성능:
+36.83%
1년 성능:
+127.26%
1일 변동 폭
$27.66
$28.78
1주일 범위
$26.00
$28.78
52주 변동 폭
$12.94
$29.85
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
28.68 | 1.74B | 0 | -198.12M | -159.74M | -3.3691 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-09 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-15 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
Pharvaris (PHVS) officer has shares withheld to cover RSU tax obligations - Stock Titan
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Pharvaris' Chief Executive Officer Sold More Than 23,000 Shares. What Does This Indicate for Shareholders? - Bitget
How (PHVS) Movements Inform Risk Allocation Models - Stock Traders Daily
PHVS Options Volatility — NASDAQ:PHVS - TradingView — Track All Markets
PHVS Options Chain — NASDAQ:PHVS - TradingView — Track All Markets
Pharvaris Insider Sold Shares Worth $647,281, According to a Recent SEC Filing - marketscreener.com
Pharvaris (PHVS) CEO sells 23,333 shares in Rule 10b5-1 trades - Stock Titan
Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) officer covers RSU taxes with 1,167 withheld shares - Stock Titan
Assessing Pharvaris (PHVS) Valuation After 2025 Earnings Loss And Deucrictibant Milestone Updates - Sahm
HC Wainwright Forecasts Pharvaris FY2030 Earnings - Defense World
HC Wainwright Weighs in on Pharvaris FY2030 Earnings - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $51.00 at Royal Bank Of Canada - Defense World
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative? - Yahoo Finance
Pharvaris moves closer to new preventive treatment for rare swelling disorder - MSN
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says - marketscreener.com
Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder - Benzinga
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Published on: 2026-04-05 13:07:26 - baoquankhu1.vn
Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)? - simplywall.st
Pharvaris (PHVS) accounting officer has 1,164 shares withheld for RSU tax obligations - Stock Titan
Pharvaris (PHVS) CTO-level executive corrects Form 3/A to 49,216 shares - Stock Titan
Pharvaris NV expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Pharvaris N.V.Ordinary Shares (NQ: PHVS - The Chronicle-Journal
Pharvaris N.V. (9EN.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pharvaris Q4 and Full Year 2025 Earnings: Net Loss Reaches €176M as Clinical Pipeline Advances - Bayelsa Watch
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones - ChartMill
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data - TipRanks
Pharvaris Q4 Loss Widens; Shares Down Pre-Bell - marketscreener.com
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - bitget.com
Pharvaris Announces Completion of Enrollment in CHAPTER-3 Study of Deucrictibant XR for HAE Prophylaxis, with Topline Data Expected in 3Q2026 - Quiver Quantitative
Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share - marketscreener.com
PHVS: Phase 3 HAE study enrollment completed; NDA submission and strong liquidity position maintained - TradingView — Track All Markets
Pharvaris (NASDAQ: PHVS) outlines HAE pipeline, capital needs and key risks - Stock Titan
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pharvaris (PHVS) deepens 2025 loss while pivotal HAE trials hit key milestones - Stock Titan
Pharvaris completes pivotal HAE study, data due in Q3 2026 - Stock Titan
Pharvaris (NASDAQ:PHVS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Does Pharvaris (PHVS) Have a Chance to Surge 59.93% According to Wall Street Analyst Predictions? - Bitget
Pharvaris NV (PHVS) price target increased by 20.90% to 45.73 - MSN
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect? - sharewise.com
Trading Systems Reacting to (PHVS) Volatility - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Tudor Investment Corp ET AL Invests $1.94 Million in Pharvaris N.V. $PHVS - MarketBeat
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
자본화:
|
볼륨(24시간):